Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection.

By Q. Gao, S. Qiu, Jia Fan, Jian Zhou, Xiao-Ying Wang, Yong-Sheng Xiao, Yang Xu, Yi-wei Li, Zhao-You Tang. Journal of Clinical Oncology, 2007

1,129 citations recorded by the source corpus.

Subfields: Immunology, Oncology

View Paper: https://www.semanticscholar.org/paper/dd80ec3a564edac4f375edf2f57ab8ae544f0338

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

In Oncology

I. Melero

Citations in the corpus

Immunogenic chemotherapy sensitizes tumors to checkpoint blockade therapy (2016, neutral): “The increased CD8 T cell:Treg cell ratio favors CD8 T-cellmediated cancer immune surveillance and is associated with beneficial outcome (Sato et al., 2005; Gao et al., 2007).”
Overexpression of PD-L1 Significantly Associates with Tumor Aggressiveness and Postoperative Recurrence in Human Hepatocellular Carcinoma (2009, methodology): “Clinically significant intratumoral immune infiltration (3), naturally acquired tumor antigen-specific T-cell responses (4), as well as natural killer cell-mediated association between depressive symptoms and survival (5) in HCC patients altogether implicate HCC as an immunogenic tumor and provide t”
The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis (2011, methodology): “We designed a broad PubMed and Embase search, using the following terms:”
Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer. (2009, background): “A high density of tumor-infiltrating FOXP3 Tregs has been associated with poor outcome in various solid tumors, including ovarian,(22,23) pancreatic,(24) and hepatocellular carcinoma.(25,26) Two groups have investigated infiltrating Tregs in CRC using FOXP3 staining.”
Advances in immunotherapy for hepatocellular carcinoma (2021, background): “I.M. receives funding from MINECO SAF2014-52361-R and SAF 2017- 83267-C2-1R; Worldwide Cancer Research Grant (15-1146); the Asociacion Española Contra el Cancer (AECC) Foundation under grant GCB15152947MELE; and the European Union’s Horizon 2020 Program (grant agreement no. 635122 PROCROP).”